The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
TLR8 signaling enhances tumor immunity by preventing tumor‐induced T‐cell senescence
Open accessAbstract
Accumulating evidence suggests the immunosuppressive microenvironments created by malignant tumors represent a major obstacle for effective anti‐tumor immunity. A better understanding of the suppressive mechanisms mediated by tumor microenvironments and the development of strategies to reverse the immune suppression are major challenges for the success of tumor immunotherapy. Here, we report that human tumor cells can induce senescence in naïve/effector T cells, exhibiting potent suppressive function in vitro and in vivo . We further show that tumor‐derived endogenous cyclic adenosine monophosphate (cAMP) is responsible for the induction of T‐cell senescence. Importantly, activation of TLR8 signaling in tumor cells can block the induction and reverse the suppression of senescent naïve and tumor‐specific T cells in vitro and in vivo , resulting in enhanced anti‐tumor immunity. These studies identify a novel mechanism of human tumor‐mediated immune suppression and provide a new strategy to reverse tumor immunosuppressive effects for tumor immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, the activation of Toll-like receptor 8 signaling in tumor cells can enhance antitumor immunity by blocking the induction of senescent T cells and tumor-specific T cells in vitro and in vivo and reversing their inhibitory effect [63].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [63]
In the citing paper
“In addition, tumor cells activate the PKA-CREB and P38 pathways by producing cAMP, thereby causing DNA damage and senescence of T cells [51, 53, 58–63].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Cellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans
Roncarolo, M. G., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., & Levings, M. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00420.x · Cited by 1,206
A2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D. E., Wong, M. K. K., Huang, X., Caldwell, S. A., Liu, K., Smith, P. T., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,095
Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer
Karin, M., Lawrence, T., & Nizet, V. (2006) · Cell · doi:10.1016/j.cell.2006.02.016 · Cited by 938
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–164 of 164
VLA-4 suppression by senescence signals regulates meningeal immunity and leptomeningeal metastasis
Li, J., Huang, D., Lei, B., Huang, J., Yang, L., Nie, M., Su, S., Zhao, Q., & Wang, Y. (2022) · eLife · doi:10.7554/elife.83272 · Cited by 15
Wang, Y., Luo, H., Cao, J., & Ma, C. (2020) · Journal of Oncology · doi:10.1155/2020/5943014 · Cited by 14
Self-citationWu, Y., Du, B., Lin, M., Ji, X., Lv, C., & Lai, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-40662-z · Cited by 14
Senescent T Cells in Age-Related Diseases
Yu, P.-J., Zhou, M. L., Liu, Y., & Du, J. (2024) · Aging and Disease · doi:10.14336/ad.2024.0219 · Cited by 16
Characteristics and mechanisms of T‐cell senescence: A potential target for cancer immunotherapy
Wu, H., Li, J., Zhang, Z., & Zhang, Y. (2024) · European Journal of Immunology · doi:10.1002/eji.202451093 · Cited by 14
Self-citationImmune cell senescence drives responsiveness to immunotherapy in melanoma
Pantelis, P., Tremoulis, D. C., Evangelou, K., Bakouros, P., Magkouta, S., Ntintas, O. A., Veroutis, D., Theocharous, G., Kostopoulos, I. V., Thanos, D.-F., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02517-1 · Cited by 14
Zhang, Y.-Y., Li, J., Li, F., Xue, S., Xu, Q., Zhang, Y., & Li, F. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04655-9 · Cited by 14
Self-citationLoss of CD96 Expression as a Marker of HIV-Specific CD8+ T-Cell Differentiation and Dysfunction
Bunet, R., Nayrac, M., Ramani, H., Sylla, M., Durand, M., Chartrand‐Lefebvre, C., Routy, J., LANDAY, A. L., Gauchat, J., Chomont, N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673061 · Cited by 15
Shi, H., Xiao, M., Li, Y., Liu, X., Na, J., Liang, C., Hua, J., Meng, Q., Wei, M., Wang, W., et al. (2025) · Theranostics · doi:10.7150/thno.112633 · Cited by 12
CD8+ T cell stressors converge on shared metabolic–epigenetic networks
Shangguan, Y., Wang, J., Ho, P., & Xu, Y. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.08.009 · Cited by 14
Microencapsulation of tumor lysates and live cell engineering with MIP-3α as an effective vaccine
Huang, F., Huang, F., Chen, B., Liu, Q., Wang, H., Zhou, S., Zhao, H., Huang, Y., Lin, Y., & Tan, G. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.123 · Cited by 12
Self-citationmiR-aculous new avenues for cancer immunotherapy
Tang, W. W., Bauer, K. M., Barba, C., Ekiz, H. A., & O’Connell, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929677 · Cited by 13
TLR8 reprograms human Treg metabolism and function
Liu, X., Li, L., & Peng, G. (2019) · Aging · doi:10.18632/aging.102223 · Cited by 12
Self-citationTan, X., Wang, Y., Long, L., Chen, H., Qu, L., Cao, X., Li, H., Chen, Z., Luo, S., & Shi, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107489 · Cited by 11
A Biological Perspective of TLR8 Signaling in Host Defense and Inflammation
Bian, F., Yan, D., Wu, X., & Yang, C. (2023) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000119 · Cited by 11
Immunosenescence: Molecular Mechanisms, Diseases, and Therapeutic Innovations
Gong, N., Pan, X., Deng, Y., Che, J., Bao, J., Wang, M., Xu, C., Liu, X., & Shi, Y. (2025) · MedComm · doi:10.1002/mco2.70515 · Cited by 14
Development of a novel TLR8 agonist for cancer immunotherapy
Wang, Y., Yang, H., Li, H., Zhao, S., Zeng, Y., Zhang, P., Lin, X., Sun, X., Wang, L., Fu, G., et al. (2020) · Molecular Biomedicine · doi:10.1186/s43556-020-00007-y · Cited by 10
Wang, Z., Chen, C., Ai, J., Gao, Y., Wang, L., Xia, S., Jia, Y., & Qin, Y. (2025) · MedComm · doi:10.1002/mco2.70048 · Cited by 12
Chen, H., Zhang, Y., Chen, X., Xu, R., Zhu, Y., He, D., Cheng, Y., Wang, Z., Qing, X., & Cao, K. (2023) · Cancer Medicine · doi:10.1002/cam4.6617 · Cited by 9
Self-citationFirmal, P., Shah, V. K., Pant, R., & Chattopadhyay, S. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13126 · Cited by 10
Kinney, B. L. C., Brammer, B., Kansal, V., Parrish, C. J., Kissick, H. T., Liu, Y., Saba, N. F., Buchwald, Z. S., El‐Deiry, M. W., Patel, M. R., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2367777 · Cited by 10
Cheng, J., Zheng, J., Ma, C., Li, Y., & Hao, H. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.010 · Cited by 8
Self-citationToll-Like Receptors and the Response to Radiotherapy in Solid Tumors: Challenges and Opportunities
Haroun, R., Naasri, S., & Oweida, A. (2023) · Vaccines · doi:10.3390/vaccines11040818 · Cited by 9
Impact and potential value of immunosenescence on solid gastrointestinal tumors
Zhang, T., Wen, R., Fan, H., Yu, Y., Jia, H., Peng, Z., Zhou, L., Yu, G., & Zhang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1375730 · Cited by 8
Immunosenescence in skeletal muscle: The role-play in cancer cachexia chessboard
Giovarelli, M., Mocciaro, E., Carnovale, C., Cervia, D., Perrotta, C., & Clementi, E. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.012 · Cited by 8
Kong, L., Tao, R., Li, Y., Wang, W.-B., & Zhao, X. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i5.2006 · Cited by 7
LADS: a powerful vaccine platform for cancer immunotherapy and prevention
Sun, J., Wang, J., Jiang, X., Xia, J., Han, Y., Chen, M., Xu, J., Deng, S., Cheng, C., & Song, H. (2024) · BMC Biology · doi:10.1186/s12915-024-02086-7 · Cited by 6
Toll-like receptor agonists as cancer therapeutics: a patent review (2014–2024)
Kumar, P., Zargar, Z. B., Chopra, K., Pawar, S. V., & Salunke, D. B. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2556819 · Cited by 5
Prognostic value and immunotherapy analysis of immune cell-related genes in laryngeal cancer
Zhang, S., Pan, J., Guo, H., Guan, X., Yan, C., Ji, L., Wu, X., & Huangfu, H. (2025) · PeerJ · doi:10.7717/peerj.19239 · Cited by 4
Senescent cancer cells in immune surveillance and evasion: mechanisms and therapeutic implications
De-chang, L., Wang, J., Wei, Y., Wu, H. Y., Yuan, S., Yang, M. J., & Sun, L. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf125 · Cited by 4
Li, Z., Luo, Y., & Shen, H. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-05473-0 · Cited by 4
Study on endogenous inhibitors against PD-L1: cAMP as a potential candidate
Huang, Q., Zang, X., Zhang, Z., Yu, H., Ding, B., Li, Z., Cheng, S., Zhang, X., Ali, M. R. K., Qiu, X., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123266 · Cited by 4
Cellular Senescence in Cancer: Mechanisms, Roles in Tumor Progression, and Therapeutic Implications
Yan, J., Zhang, Y., Mao, G., Yu, J., Zhou, T., & Hao, J. (2025) · MedComm – Oncology · doi:10.1002/mog2.70029 · Cited by 3
Self-citationDevelopment of therapeutic cancer vaccines based on cancer immunity cycle
Zhang, J., Zheng, Y., Xu, L., Gao, J., Ou, Z., Zhu, M., & Wang, W. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1134-6 · Cited by 2
Toll-like receptors: versatile players in tumor
Yang, Y., & Pi, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1735188 · Cited by 2
Senescent T Cells: The Silent Culprit in Acute Myeloid Leukemia Progression?
Zhang, X., & Liu, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312550 · Cited by 2
Gao, X., Shen, X., Huang, S., & Huang, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-02127-9 · Cited by 3
Targeting Toll-Like Receptors in Cancer Immunotherapy
Saleki, K., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_192-1 · Cited by 2
T Cell Senescence and Tumor Immunotherapy
Liu, X., & Peng, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-64597-1_136-1 · Cited by 2
Self-citationRen, P., & Zhang, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1010023 · Cited by 1
Self-citationcPLA2α-driven Cox-2/PGE2 axis promotes hypoxia-induced senescence in Jurkat T cells
Jung, J., Yang, Y., & Kim, Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152894 · Cited by 1
Zhang, Y., Zhou, X., Wei, Y. Y., Zhang, H., Zhao, Y., Tong, H., Jiang, Z., Li, G., Jiang, Y., Yin, X., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117583 · Cited by 1
Self-citationT Cell Senescence and Tumor Immunotherapy
Liu, X., & Peng, G. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_136 · Cited by 1
Self-citationDang, Y., Huang, J., Chen, L., & Xu, S. (2024) · Annals of Human Genetics · doi:10.1111/ahg.12548 · Cited by 1
Exploring the role of cellular senescence in cancer prognosis across multiple tumor types
Xu, Q., & Feng, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1378356 · Cited by 1
Rodríguez, R., & Johanna, I. (2021)
Zhong, Z., Hong, M. H., Chen, X., Xi, Y., Xu, Y., Kong, D., Deng, J., Li, Y., Hu, R., Sun, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12051330
Zhong, Z., Hong, M. H., Chen, X., Xi, Y., Xu, Y., Kong, D., Deng, J., Li, Y., Hu, R., Sun, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12051321
Zhong, Z., Hong, M. H., Chen, X., Xi, Y., Xu, Y., Kong, D., Deng, J., Li, Y., Hu, R., Sun, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12051339
Targeting Toll-Like Receptors in Cancer Immunotherapy
Saleki, K., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_192
Zhong, Z., Hong, M., Chen, X., Xi, Y., Xu, Y., Kong, D., Deng, J., Li, Y., Hu, R., Sun, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12051300
Zhong, Z., Hong, M., Chen, X., Xi, Y., Xu, Y., Kong, D., Deng, J., Li, Y., Hu, R., Sun, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12051306
Zhong, Z., Hong, M., Chen, X., Xi, Y., Xu, Y., Kong, D., Deng, J., Li, Y., Hu, R., Sun, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12051315
Wu, Z., Uhl, B., Gires, O., & Reichel, C. A. (2024) · Figshare · doi:10.6084/m9.figshare.26578268
Zhong, Z., Hong, M., Chen, X., Xi, Y., Xu, Y., Kong, D., Deng, J., Li, Y., Hu, R., Sun, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12051345
Xiong, Y., WANG, Y., Zhang, J., Zhao, N., Zhang, H., Zhang, A., Zhao, D., Yu, Z., Yin, Y., Song, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13192471
Li, A., Liu, J., Wu, H., Jin, Y., Zhang, H., Zhang, Z., Jiang, S., & Zhang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1711401
Dual roles of immunosenescence in cancer immunotherapy
Yu, Y., Sun, L., & Fan, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1779141
Impact of respiratory viral infections on tumor progression in Non-Small-Cell Lung Carcinoma (NSCLC)
Angrini, M. (2021) · theses.fr (ABES) · doi:10.70675/9c027d88z3675z44adza870z1802353e674a
Single cell multi-OMICS analysis of Treg biology in cancer
Richer, W. (2021) · theses.fr (ABES) · doi:10.70675/97f429e9z2993z4b78z88dezf46fae0d3a30
Modulation de l'activation des lymphocytes T et des réponses anti-tumorales par le fer
Porte, S. (2022) · theses.fr (ABES) · doi:10.70675/4251e200zd50ez4a76zb869zb97fa8d3e879
Zhao, R., Li, Y., Zhu, R., Zong, R., Sun, M., Liu, M., & Guo, H. C. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105385
Fu, J., Pei, S., Du, J., Deng, X., Wang, X., Li, T., Huang, H., Ye, J., Xu, J., Wang, X., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.09.004
Self-citation
Metadata
- Authors
- Ye, J., Ma, C., Hsueh, E. C., Dou, J., Mo, W., Liu, S., Han, B., Huang, Y., Zhang, Y., Varvares, M. A., Hoft, D. F., & Peng, G.
- Affiliations
- Saint Louis University (US)
- Corresponding author
- Peng, Guangyong
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2014-09-17
- Volume
- 6
- Issue
- 10
- Pages
- 1294-1311
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC4287933
- OpenAlex
- W2000656984
- Cited by
- 161
- References
- 56
- Citations by year
- 2026: 6 · 2025: 24 · 2024: 24 · 2023: 14 · 2022: 16 · 2021: 27 · 2020: 22 · 2019: 6 · 2018: 13 · 2017: 5 · 2016: 1 · 2015: 3
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- American Cancer Society (RSG‐10‐160‐01‐LIB)
- Melanoma Research Alliance
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- T cell senescence, tumor immunosuppression, tumor microenvironment, cyclic AMP, antitumor immunity, cancer immunotherapy, tumor-specific T cells
- MeSH terms
- Cyclic AMP, Animals, Cells, Cultured, Flow Cytometry, Humans, Neoplasms, T-Lymphocytes, Blotting, Western, Signal Transduction, CD4-Positive T-Lymphocytes, Immunotherapy, Adoptive, Mice, SCID, Mice, Inbred NOD, Cellular Senescence, Mice, Knockout, Coculture Techniques, Xenograft Model Antitumor Assays, RNA Interference, Cell Line, Tumor, Toll-Like Receptor 8, Interleukin Receptor Common gamma Subunit, Tumor Microenvironment, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
